Perspective Chapter: Development of Exosomes for Esthetic Use
While there are thousands of peer-reviewed papers on exosomes, most of the work has been done in the medical field. Studies and clinical trials on exosome-related products for the esthetic industry have just begun to be a regular occurrence. One of the reasons for this is a lack of regulatory approv...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/87848 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | While there are thousands of peer-reviewed papers on exosomes, most of the work has been done in the medical field. Studies and clinical trials on exosome-related products for the esthetic industry have just begun to be a regular occurrence. One of the reasons for this is a lack of regulatory approval for any exosome use. The FDA does not regulate topical cosmetic use, while only a few exosomes are registered on the International Cosmetic Ingredient Dictionary (ICID) of the Personal Care Product Council (PCPC), so most esthetic providers are utilizing exosomes in this manner. Clinical uses for exosomes in esthetic practice include the treatment of burns, active acne, atopic dermatitis, and chronic skin irritations. When used in combination with energy-based device treatment, exosomes reduce inflammation and redness, improve the rapidity of healing for laser and microneedling patients, and reduce the tendency for fibrosis and thick hypertrophic scar formation when used topically. Byong Cho is the CEO & CTO of ExoCoBio, one of the four largest exosome companies globally. He has developed a large research, development, and GMP manufacturing facility just south of Seoul, Korea. His topic, the development of exosomes for clinical esthetic use, will take us through the process of developing a safe and cost-effective biological regenerative product while staying in line with regulatory limitations. |
|---|---|
| ISBN: | 978-1-83768-949-1 |
| DOI: | 10.5772/intechopen.111846 |